Shattuck Labs Announces Participation in Upcoming March Investor Conferences

Shattuck Labs, Inc. (NASDAQ: STTK), a clinical-stage biotechnology company focused on innovative therapies for inflammatory and immune-mediated diseases, has announced its participation in two upcoming investor conferences. Management will present at the TD Cowen 46th Annual Health Care Conference on March 2, 2026, at 9:10 AM ET in Boston, MA, led by CEO Dr. Taylor Schreiber. The conference will include a corporate presentation and one-on-one meetings with investors.

Following this, Dr. Schreiber will also attend the Leerink Partners 2026 Global Health Care Conference on March 10-11, 2026, in Miami, FL, engaging in one-on-one meetings with investors. Interested investors can access live audio webcasts of Shattuck's presentations through the Investor Relations section of their website, with replays available for approximately 30 days after the events.

Shattuck Labs is advancing its lead candidate, SL-325, a potentially first-in-class antibody designed to block Death Receptor 3 (DR3). This innovative therapy aims to provide a robust and sustained blockade of the established DR3/TL1A pathway, showing promise through preclinical studies that highlight its superior binding and activity compared to conventional TL1A antibodies. Currently, SL-325 is being evaluated in a Phase 1 clinical trial, demonstrating a favorable safety profile in non-human primate studies.

Shattuck Labs is headquartered in Austin, Texas, and Durham, North Carolina, specializing in developing advanced protein engineering techniques and novel TNF receptor therapeutics. The company's commitment to pioneering new treatments positions it as a noteworthy entity in the biopharmaceutical landscape. For further details, visit their website at www.shattucklabs.com.

Shattuck Labs, Inc. (NASDAQ: STTK), a clinical-stage biotechnology firm, is positioning itself for increased visibility and potential investor interest by participating in key healthcare investor conferences this March. This strategic move is essential for companies like Shattuck that are still in the clinical development phase, as it helps to build investor confidence and attract funding, which is crucial for continued research and development.

Shattuck's entry into the market with SL-325, a novel DR3-blocking antibody aimed at treating inflammatory and immune-mediated diseases, signals a strong commitment to addressing significant health needs in a burgeoning field. Their preclinical studies demonstrating superior efficacy compared to existing antibodies may further bolster their competitive position. As they prepare to present at the TD Cowen 46th Annual Health Care Conference and the Leerink Partners 2026 Global Health Care Conference, investors may closely watch for updates on SL-325’s Phase 1 clinical trial results, which could catalyze stock movement.

Investors should note that participation in such conferences often leads to enhanced engagement from Wall Street, especially if the presentations underscore positive trial results and forward-looking statements regarding the drug's commercial potential. The high affinity binding and favorable safety profile observed in early studies provide a compelling justification for investment.

However, potential investors should remain cautious. The clinical-stage biotechnology sector can be highly volatile, subject to regulatory approvals and market conditions. Interested parties are encouraged to utilize webcasts from the presentations for real-time insights and to stay informed on the stock's performance around these pivotal events. Overall, while Shattuck Labs carries significant promise, continued diligence and market monitoring are advised as they navigate this critical phase of development.